see more

UNITED STATES - FEBRUARY 01: Roche's colon-cancer drug Avastin featured in a Cambridge, Massachusetts pharmacy Wednesday, February 1st. Genentech Inc. said requests by U.S. regulators will delay consideration of the colon-cancer drug Avastin as a treatment for breast cancer. (Photo by Jb Reed/Bloomberg via Getty Images)

UNITED STATES - FEBRUARY 01:  Roche's colon-cancer drug Avastin featured in a Cambridge, Massachusetts pharmacy Wednesday, February 1st. Genentech Inc. said requests by U.S. regulators will delay consideration of the colon-cancer drug Avastin as a treatment for breast cancer.  (Photo by Jb Reed/Bloomberg via Getty Images)

see more

A tank manufacturing the cancer drug Avastin sits inside the production laboratory at the Roche Holding AG headquarters in Basel, Switzerland, on Tuesday, Sept. 8, 2015. Roche Holding AG Chief Executive Officer Severin Schwan blasted a U.K. decision to stop funding some cancer drugs, calling the choice 'stupid'. Photographer: Chris Ratcliffe/Bloomberg via Getty Images

A tank manufacturing the cancer drug Avastin sits inside the production laboratory at the Roche Holding AG headquarters in Basel, Switzerland, on Tuesday, Sept. 8, 2015. Roche Holding AG Chief Executive Officer Severin Schwan blasted a U.K. decision to stop funding some cancer drugs, calling the choice 'stupid'. Photographer: Chris Ratcliffe/Bloomberg via Getty Images

see more

Severin Schwan, chief executive officer Roche Holding AG, poses for a photograph following an interview in London, U.K., on Wednesday, Dec. 6, 2017. Roche's new lung cancer combination therapy showed it works in a broad range of patients, but the complex study left investors and analysts split over its meaning. Photographer: Chris J. Ratcliffe/Bloomberg via Getty Images

Severin Schwan, chief executive officer Roche Holding AG, poses for a photograph following an interview in London, U.K., on Wednesday, Dec. 6, 2017. Roche's new lung cancer combination therapy showed it works in a broad range of patients, but the complex study left investors and analysts split over its meaning. Photographer: Chris J. Ratcliffe/Bloomberg via Getty Images

see more

The Roche Holding AG logo sits on the edge of a medication box next to tablets on a pharmacy counter in this arranged photograph in London, U.K., on Monday, Dec. 14, 2015. European pharmaceuticals stocks in 2015 have outperformed the Stoxx 600 Index by 1.2 percentage points in U.S. dollar terms. Photographer: Simon Dawson/Bloomberg via Getty Images

The Roche Holding AG logo sits on the edge of a medication box next to tablets on a pharmacy counter in this arranged photograph in London, U.K., on Monday, Dec. 14, 2015. European pharmaceuticals stocks in 2015 have outperformed the Stoxx 600 Index by 1.2 percentage points in U.S. dollar terms. Photographer: Simon Dawson/Bloomberg via Getty Images

see more

The company logo for Roche Holding AG is seen on a glass doorway at the company's headquarters in Basel, Switzerland, on Wednesday, Feb. 1, 2017. Roche Holding AG is bracing for slower earnings growth this year as its ageing cancer blockbusters face competition and the Swiss drugmaker readies a new generation of medicines. Photographer: Michele Limina/Bloomberg via Getty Images

The company logo for Roche Holding AG is seen on a glass doorway at the company's headquarters in Basel, Switzerland, on Wednesday, Feb. 1, 2017. Roche Holding AG is bracing for slower earnings growth this year as its ageing cancer blockbusters face competition and the Swiss drugmaker readies a new generation of medicines. Photographer: Michele Limina/Bloomberg via Getty Images